title: Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?
abstract: OBJECTIVE
  To assess the cost effectiveness and cost effectiveness acceptability of symptom control delivered by shared care (SCSC) and aggressive treatment delivered in hospital (ATH) for established rheumatoid arthritis (RA).
  
  
  METHODS
  Economic data were collected within the British Rheumatoid Outcome Study Group randomised controlled trial of SCSC and ATH. A broad perspective was used (UK National Health Service, social support services and patients). Cost per quality adjusted life year (QALY) gained, net benefit statistics and cost effectiveness acceptability curves were estimated. Costs and outcomes were discounted at 3.5%. Sensitivity analysis tested the robustness of the results to analytical assumptions.
  
  
  RESULTS
  The mean (SD) cost per person was 4540 pounds (4700) in the SCSC group and 4440 pounds (4900) in the ATH group. The mean (SD) QALYs per person for 3 years were 1.67 (0.56) in the SCSC group and 1.60 (0.60) in the ATH group. If decision makers are prepared to pay > or = 2000 pounds to gain 1 QALY, SCSC is likely to be cost effective in 60-90% of cases.
  
  
  CONCLUSIONS
  The primary economic analysis and sensitivity analyses indicate that SCSC is likely to be more cost effective than ATH in 60-90% of cases. This result seems to be robust to assumptions required by the analysis. This study is one of a limited number of randomised controlled trials to collect detailed resource use and health status data and estimate the costs and QALYs of treatment for established RA. This trial is one of the largest RA studies to use the EuroQol.
authors.affiliation: Health Economics Research at Manchester, University of Manchester, Manchester, UK. linda.davies@manchester.ac.uk
authors.forename: Linda Mary
authors.initials: LM
authors.lastname: Davies
authors.forename: Emily Anne
authors.initials: EA
authors.lastname: Fargher
authors.forename: Karen
authors.initials: K
authors.lastname: Tricker
authors.forename: Peter
authors.initials: P
authors.lastname: Dawes
authors.forename: David L
authors.initials: DL
authors.lastname: Scott
authors.forename: Deborah
authors.initials: D
authors.lastname: Symmons
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000191:economics / Q000628:therapy*; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics / Q000379:methods; D005194:Family Practice / Q000191:economics / Q000379:methods*; D017048:Health Care Costs; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D019057:Quality-Adjusted Life Years; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D018501:Antirheumatic Agents